These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32298204)

  • 1. Rubella seroprevalence using residual samples from the South African measles surveillance program: a cross-sectional analytic study.
    Motaze NV; Makhathini L; Smit SB; Adu-Gyamfi CG; Fortuin M; Wiysonge CS; Suchard SM
    Hum Vaccin Immunother; 2020 Nov; 16(11):2656-2662. PubMed ID: 32298204
    [No Abstract]   [Full Text] [Related]  

  • 2. Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.
    Wang Z; Yan R; He H; Li Q; Chen G; Yang S; Chen E
    PLoS One; 2014; 9(2):e89361. PubMed ID: 24586717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measles and rubella serosurvey identifies rubella immunity gap in young adults of childbearing age in Zambia: The added value of nesting a serological survey within a post-campaign coverage evaluation survey.
    Hayford K; Mutembo S; Carcelen A; Matakala HK; Munachoonga P; Winter A; Wanyiri JW; Searle K; Mwansa FD; Mwiche A; Phiri C; Book C; Thuma PE; Moss WJ
    Vaccine; 2019 Apr; 37(17):2387-2393. PubMed ID: 30905529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey.
    Amela C; Pachón I; de Ory F
    Eur J Epidemiol; 2003; 18(1):71-9. PubMed ID: 12705626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measles and rubella IgG seroprevalence in persons 6 month-35 years of age, Mongolia, 2016.
    Nogareda F; Gunregjav N; Sarankhuu A; Munkhbat E; Ichinnorov E; Nymadawa P; Wannemuehler K; Mulders MN; Hagan J; Patel MK
    Vaccine; 2020 May; 38(26):4200-4208. PubMed ID: 32381479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
    Matter L; Germann D; Bally F; Schopfer K
    Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology of rubella infection in Cameroon: a 7-year experience of measles and rubella case-based surveillance, 2008-2014.
    Nimpa Mengouo M; Ndze VN; Baonga F; Kobela M; Wiysonge CS
    BMJ Open; 2017 Apr; 7(4):e012959. PubMed ID: 28389483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using Locally Derived Seroprevalence Data on Measles, Mumps, Rubella, and Varicella by Birth Cohort to Determine Risks for Vaccine-Preventable Diseases During International Travel.
    Rosario-Rosario G; Gareca M; Kincaid H; Knouse MC
    J Travel Med; 2015; 22(6):396-402. PubMed ID: 26412393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seroprevalence of measles, mumps and rubella antibodies in Luxembourg: results from a national cross-sectional study.
    Mossong J; Putz L; Schneider F
    Epidemiol Infect; 2004 Jan; 132(1):11-8. PubMed ID: 14979584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MMR vaccination, measles epidemiology and sero-surveillance in the Republic of Ireland.
    Johnson H; Hillary IB; McQuoid G; Gilmer BA
    Vaccine; 1995 Apr; 13(6):533-7. PubMed ID: 7483773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mumps serological surveillance following 10 years of a one-dose mumps-containing-vaccine policy in Fujian Province, China.
    Li D; Zhang H; You N; Chen Z; Yang X; Zhang H; Zhou Y; Zheng N; Pan W
    Hum Vaccin Immunother; 2022 Nov; 18(6):2096375. PubMed ID: 35950847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroprevalence of measles, mumps, rubella, and varicella zoster virus antibodies among healthcare students: analysis of vaccine efficacy and cost-effectiveness.
    Ödemiş Í; Köse Ş; Akbulut Í; Albayrak H
    Rev Esp Quimioter; 2019 Dec; 32(6):525-531. PubMed ID: 31642641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy.
    Madi N; Altawalah H; Alfouzan W; Al-Nakib W; Al-Roumi E; Jeragh A
    J Med Virol; 2020 Aug; 92(8):963-970. PubMed ID: 31919861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When, and how, should we introduce a combination measles-mumps-rubella (MMR) vaccine into the national childhood expanded immunization programme in South Africa?
    Cameron NA
    Vaccine; 2012 Sep; 30 Suppl 3():C58-60. PubMed ID: 22939023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of antibodies against measles, mumps, and rubella before and after vaccination of school-age children with three different triple combined viral vaccines, Rio Grande do Sul, Brazil, 1996.
    dos Santos BA; Stralioto SM; Siqueira MM; Ranieri TS; Bercini M; Schermann MT; Wagner MB; Silveira TR
    Rev Panam Salud Publica; 2006 Nov; 20(5):299-306. PubMed ID: 17316487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do adolescents need a rubella vaccination campaign? Rubella serosurvey among healthy children in Hangzhou, China.
    Wang X; Xu Y; Zhang X; Zhang X; Du J; Che X; Gu W; Wang J; Jiang W; Liu Y
    Hum Vaccin Immunother; 2023 Aug; 19(2):2254536. PubMed ID: 37750387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of vaccine-preventable and non-vaccine-preventable infections in migrants in Spain.
    Norman FF; Comeche B; Martínez-Lacalzada M; Pérez-Molina JA; Gullón B; Monge-Maillo B; Chamorro S; López-Vélez R
    J Travel Med; 2021 Jun; 28(4):. PubMed ID: 33611577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology of acute rubella infection in Zambia during the pre-vaccination period (2005-2016) as a baseline for monitoring rubella epidemiology in the post-rubella vaccine introduction era.
    Mazaba ML; Siziya S; Monze M; Cohen D
    BMC Infect Dis; 2020 Feb; 20(1):101. PubMed ID: 32013873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of antibodies against measles, mumps and rubella in the childhood population in Singapore, 2008-2010.
    Ang LW; Lai FY; Tey SH; Cutter J; James L; Goh KT
    Epidemiol Infect; 2013 Aug; 141(8):1721-30. PubMed ID: 22999024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the effect of measles and rubella mass vaccination campaigns on seroprevalence in India: a before-and-after cross-sectional household serosurvey in four districts, 2018-2020.
    Murhekar MV; Gupta N; Hasan AZ; Kumar MS; Kumar VS; Prosperi C; Sapkal GN; Thangaraj JWV; Kaduskar O; Bhatt V; Deshpande GR; Thankappan UP; Bansal AK; Chauhan SL; Grover GS; Jain AK; Kulkarni RN; Sharma SK; Chaaithanya IK; Kharwal S; Mishra SK; Salvi NR; Sharma S; Sarmah NP; Sabarinathan R; Duraiswamy A; Rani DS; Kanagasabai K; Lachyan A; Gawali P; Kapoor M; Shrivastava AK; Chonker SK; Tilekar B; Tandale BV; Ahmad M; Sangal L; Winter A; Mehendale SM; Moss WJ; Hayford K
    Lancet Glob Health; 2022 Nov; 10(11):e1655-e1664. PubMed ID: 36240831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.